86 related articles for article (PubMed ID: 27419052)
1. Activities of wild-type and variant tissue-type plasminogen activators retained on vascular endothelial cells.
Suzuki Y; Sano H; Tomczyk M; Brzoska T; Urano T
FEBS Open Bio; 2016 May; 6(5):469-76. PubMed ID: 27419052
[TBL] [Abstract][Full Text] [Related]
2. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
Yasui H; Suzuki Y; Sano H; Suda T; Chida K; Dan T; Miyata T; Urano T
Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
[TBL] [Abstract][Full Text] [Related]
3. Accelerated fibrinolysis and its propagation on vascular endothelial cells by secreted and retained tPA.
Urano T; Suzuki Y
J Biomed Biotechnol; 2012; 2012():208108. PubMed ID: 23118500
[TBL] [Abstract][Full Text] [Related]
4. Surface-retained tPA is essential for effective fibrinolysis on vascular endothelial cells.
Suzuki Y; Yasui H; Brzoska T; Mogami H; Urano T
Blood; 2011 Sep; 118(11):3182-5. PubMed ID: 21791417
[TBL] [Abstract][Full Text] [Related]
5. Clot lysis mediated by cultured human microvascular endothelial cells.
Speiser W; Anders E; Binder BR; Müller-Berghaus G
Thromb Haemost; 1988 Dec; 60(3):463-7. PubMed ID: 3149047
[TBL] [Abstract][Full Text] [Related]
6. Tissue-type plasminogen activator-binding RNA aptamers inhibiting low-density lipoprotein receptor family-mediated internalisation.
Bjerregaard N; Bøtkjær KA; Helsen N; Andreasen PA; Dupont DM
Thromb Haemost; 2015 Jul; 114(1):139-49. PubMed ID: 25855589
[TBL] [Abstract][Full Text] [Related]
7. Clot penetration and retention by plasminogen activators promote fibrinolysis.
Marcos-Contreras OA; Ganguly K; Yamamoto A; Shlansky-Goldberg R; Cines DB; Muzykantov VR; Murciano JC
Biochem Pharmacol; 2013 Jan; 85(2):216-22. PubMed ID: 23098998
[TBL] [Abstract][Full Text] [Related]
8. Zinc delays clot lysis by attenuating plasminogen activation and plasmin-mediated fibrin degradation.
Henderson SJ; Stafford AR; Leslie BA; Kim PY; Vaezzadeh N; Ni R; Fredenburgh JC; Weitz JI
Thromb Haemost; 2015 Jun; 113(6):1278-88. PubMed ID: 25789495
[TBL] [Abstract][Full Text] [Related]
9. The effector roles of kringle 1 and kringle 2 in the enzymatic properties of recombinant tissue-type plasminogen activator as revealed by generation of recombinant molecules containing each kringle linked to the protease domain.
Rydzewski A; Castellino FJ
Arch Biochem Biophys; 1993 Jan; 300(1):472-82. PubMed ID: 8424682
[TBL] [Abstract][Full Text] [Related]
10. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
11. Novel situations of endothelial injury in stroke--mechanisms of stroke and strategy of drug development: novel mechanism of the expression and amplification of cell surface-associated fibrinolytic activity demonstrated by real-time imaging analysis.
Suzuki Y; Urano T
J Pharmacol Sci; 2011; 116(1):19-24. PubMed ID: 21498960
[TBL] [Abstract][Full Text] [Related]
12. Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator.
Shenkman B; Livnat T; Budnik I; Tamarin I; Einav Y; Martinowitz U
Blood Coagul Fibrinolysis; 2012 Dec; 23(8):729-33. PubMed ID: 22918041
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of tPA-dependent provisional extracellular fibrin matrix degradation by human recombinant soluble melanotransferrin.
Bertrand Y; Demeule M; Rivard GE; Béliveau R
Biochim Biophys Acta; 2006 Oct; 1763(10):1024-30. PubMed ID: 16979249
[TBL] [Abstract][Full Text] [Related]
14. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
[TBL] [Abstract][Full Text] [Related]
15. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
Wu JH; Diamond SL
J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
[TBL] [Abstract][Full Text] [Related]
16. Fibrin affinity of erythrocyte-coupled tissue-type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo.
Ganguly K; Goel MS; Krasik T; Bdeir K; Diamond SL; Cines DB; Muzykantov VR; Murciano JC
J Pharmacol Exp Ther; 2006 Mar; 316(3):1130-6. PubMed ID: 16284278
[TBL] [Abstract][Full Text] [Related]
17. Herpesviruses enhance fibrin clot lysis.
Gershom ES; Vanden Hoek AL; Meixner SC; Sutherland MR; Pryzdial EL
Thromb Haemost; 2012 Apr; 107(4):760-8. PubMed ID: 22318336
[TBL] [Abstract][Full Text] [Related]
18. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
19. The mast cell as site of tissue-type plasminogen activator expression and fibrinolysis.
Sillaber C; Baghestanian M; Bevec D; Willheim M; Agis H; Kapiotis S; Füreder W; Bankl HC; Kiener HP; Speiser W; Binder BR; Lechner K; Valent P
J Immunol; 1999 Jan; 162(2):1032-41. PubMed ID: 9916730
[TBL] [Abstract][Full Text] [Related]
20. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
Hare TR; Gardell SJ
Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]